Lyra Therapeutics posts new corporate presentation

Lyra Therapeutics, Inc. filed a report noting that on September 4, 2025 it posted a new corporate presentation on its website.

Rhea-AI Filing Summary

Lyra Therapeutics, Inc. filed a report noting that on September 4, 2025 it posted a new corporate presentation on its website. Company representatives may use this presentation in discussions with investors, analysts, and other interested parties.

The presentation is provided as Exhibit 99.1 to the report and is incorporated by reference, giving stakeholders a centralized source for updated company information. Lyra’s common stock trades on the Nasdaq Capital Market under the symbol LYRA.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lyra Therapeutics (LYRA) disclose in this 8-K filing?

Lyra Therapeutics disclosed that it posted a corporate presentation to its website on September 4, 2025, for use in discussions with investors, analysts, and other parties.

What is included as Exhibit 99.1 in Lyra Therapeutics’ 8-K?

Exhibit 99.1 contains a corporate presentation by Lyra Therapeutics, Inc. that company representatives may use in presentations or discussions with investors, analysts, or other parties.

When did Lyra Therapeutics post its new corporate presentation?

Lyra Therapeutics posted its corporate presentation on September 4, 2025, the same date referenced as the event date in the report.

Where is Lyra Therapeutics’ corporate headquarters located?

Lyra Therapeutics’ principal executive offices are located at 480 Arsenal Way, Watertown, Massachusetts 02472.

On which exchange is Lyra Therapeutics’ common stock listed and under what symbol?

Lyra Therapeutics’ common stock is listed on The Nasdaq Capital Market under the trading symbol LYRA.

Who signed this Lyra Therapeutics 8-K filing?

The report was signed on behalf of Lyra Therapeutics, Inc. by Jason Cavalier, the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/04/2025 - 08:01 AM Learn about SEC filing dates

NASDAQ false 0001327273 0001327273 2025-09-04 2025-09-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 4, 2025

Lyra Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-39273		84-1700838
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

480 Arsenal Way Watertown, Massachusetts		02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 393-4600

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		LYRA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 4, 2025, Lyra Therapeutics, Inc. (the “Company”) posted a corporate presentation to its website that representatives of the Company may use from time to time in presentations or discussions with investors, analysts or other parties. A copy of the presentation is attached as Exhibit 99.1, which is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation by Lyra Therapeutics, Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Lyra Therapeutics, Inc.
Date: September 4, 2025				By:		/s/ Jason Cavalier
						Jason Cavalier
						Chief Financial Officer